The July 25 edition of "The Tan Sheet" continues coverage of the OTC industry's biggest story of the past two years -- Johnson & Johnson's OTC manufacturing issues and recalls. Our cover story looks into the report produced by a special committee of J&J directors, in response to a shareholder lawsuit, that identifies root causes behind the company's quality control lapses. On the inside of this week's issue, we take a look at J&J's second-quarter results and the encouraging signs for its consumer business.
"The Tan Sheet" also has follow-up coverage of FDA's new dietary ingredient notification draft guidance -- what it might mean for probiotics supplements and how FDA might go about enforcing the guidance.
Of course, there's plenty more as well, including news from Procter & Gamble, Abbott Nutrition and the U.N.'s Codex Alimentarius Commission.
J&J Directors Find Root Causes But Little Blame For OTC Quality Issues
A report by a Johnson & Johnson special committee finds organizational and middle management changes at the firm were the root causes of manufacturing and quality control lapses in the OTC drug business.
International Panel’s Nutrient Value Guideline May Boost Supplement Exports
Dietary supplement firms soon could export products internationally without having to reformulate to accommodate local nutrient value regulations.
NDI Notification Enforcement Ramp-Up Likely To Target “Low-Hanging Fruit”
Legitimate supplement firms should not need phased-in enforcement of the new dietary ingredient notification regulations, says Anthony Young, general counsel to the American Herbal Products Association.
- P&G Recalls Mouthwashes, Shuts Down Colombian Manufacturer
- J&J Consumer Recaptures Growth, Plans To Restore Most OTCs By Mid-2012
- NDI Guidance Microorganism Stance Could Strain Probiotics Development
- Private Third-Party Audits Could Enhance FDA’s Manufacturing Risk Analysis
BUSINESS & FINANCE
- Abbott Says Nutritionals Can Succeed Without M&A Activity
- Improving Credibility Key To Nutricosmetic Success In U.S. – Datamonitor
RESEARCH & DEVELOPMENT
- Discontinuing Aspirin Regimen Linked To Increased Heart Attack Risk
- Research & Development In Brief
- Dan Schiff (email@example.com)